Compare Invesco DB Agriculture Fund (DBA) vs Cassava Sciences Inc (FLNA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Invesco DB Agriculture Fund vs Cassava Sciences Inc — how do they compare? Invesco DB Agriculture Fund trades at $28.32 (market cap $1.32B), while Cassava Sciences Inc trades at $0.83 (market cap $39.40M). The key difference: Invesco DB Agriculture Fund is far larger — about 33.5× Cassava Sciences Inc's market cap, and Invesco DB Agriculture Fund is trading nearer its 52-week high, Cassava Sciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Invesco DB Agriculture Fund for 24 Days and Cassava Sciences Inc for 37 Days on average.
| DBA | FLNA | |
|---|---|---|
Market Cap | $1.32B | $39.40M |
Volume | 771,657 | 759,018 |
52-Week High | $29.49 | $4.64 |
52-Week Low | $25.44 | $0.68 |
Typical Hold Time | 24 Days | 37 Days |
Sector | — | Health |
Enterprise Value | — | -$43.28M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DBA (Invesco DB Agriculture Fund ETF) trades at $28.295, down 0.68% today, with a bearish technical signal from moving averages but neutral oscillators. The ETF has delivered strong 12.4% YTD returns, outperforming the S&P 500 in recent months according to Zacks Investment Research (2026-07-30). Recent news highlights agricultural ETF strength driven by weather risks and geopolitical tensions, though the fund carries a relatively high 0.85% expense ratio.
The agricultural commodities exposure positions DBA for potential upside from supply chain disruptions and global demand, but investors face volatility risks from commodity price swings and geopolitical uncertainty. Analyst sentiment remains mixed with Seeking Alpha maintaining a Hold rating (2026-09-22) while noting bullish long-term trends since 2020.
FLNA trades at $0.84, up 2.72% today, with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with ROE at -55.79% and ROA at -35.34%, though valuation ratios like EV/EBITDA of 1.03 and P/B of 0.62 suggest potential undervaluation. Recent FDA clearance for epilepsy drug trials provides a positive catalyst, but negative cash flow trends and zero revenue remain concerns.
The outlook hinges on clinical trial success and revenue generation. Analyst consensus is bullish with 67% buy ratings, but high execution risk and cash burn require careful monitoring. Near-term catalysts include Phase 2a trial initiation in 2027, while financial sustainability remains the primary challenge for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Invesco DB Agriculture Fund
The index, which is comprised of one or more underlying commodities ("index commodities"), is intended to reflect the agricultural sector. The fund pursues its investment objective by investing in a portfolio of exchange-traded futures.
Read more on DBA →About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →
